# April 11 (Saturday) Ballroom I

## Keynote Speech [A]

**Moderator: Shinn-Zong Lin (林欣榮)、Chung-Liang Chien (錢宗良)**

| | | |
|---|---|---|
| 08:50-09:30 | K1-I1 | Discovery of Muse Cells Shifts the Paradigm of Stem Cell Therapy<br>*Mari Dezawa (Japan)* |
| 09:30-10:10 | K1-I2 | Hints to Improve the Success Rate of Cellular Therapy Based on Mesenchymal Stromal Cells (Mscs): Secretome of Senescent Mscs Has a Negative Paracrine Effect on Healthy Cells by Reducing the Stemness and Promoting the Senescence<br>*Umberto Galderisi (Italy)* |

## A1

### Emerging Drug Targets in Development and Discovery

| | | |
|---|---|---|
| 10:30-11:00 | A1-I1 | AC5 Surgical Hemostat™ Is an Effective Hemostatic Agent in Anticoagulated Animals Using a Non-Compressible, Penetrating Liver Wound Model<br>*Rutledge Ellis-Behnke (Germany)* |
| 11:00-11:30 | A1-I2 | Engineering 3D Hydrogel for Biological Application<br>*Hossein Hosseinkhani (U.S.A)* |
| 11:30-12:00 | A1-I3 | Hedgehog Stemness Pathway Maintains Cell Survival and Drives Drug Resistance through HGF/MET Signaling in Lung Adenocarcinoma<br>*Cheng-Wen Wu 吳成文 (Taiwan)* |

## Luncheon Seminar

### Gwo Xi Stem Cell Applied Technology Co., Ltd. 國璽幹細胞應用技術股份有限公司

| | | |
|---|---|---|
| 12:00-13:00 | L1 | TBA |

## B1

### Adipose-Derived Stem Cell Plasticity for Regenerative Medicine

| | | |
|---|---|---|
| 13:00-13:30 | B1-I1 | The Peripheral Hormonal Control of Stem Cells<br>*Paolo Fiorina (U.S.A)* |
| 13:30-14:00 | B1-I2 | Chondrogenesis from Stem Cells<br>*Gun Il Im (Korea)* |
| 14:40-14:30 | B1-I3 | Physical Exercise-Induced Hippocampal Neurogenesis and Antidepressant Effects Are Mediated by the Adipocyte Hormone Adiponectin<br>*Kwok Fai So (Hong Kong)* |

## C1

### Stem Cell Technology for Neurodegenerative Diseases

| | | |
|---|---|---|
| 14:50-15:20 | C1-I1 | Umbilical Cord Lining Cells-Derived Induced Pluripotent Stem Cells as a Source of Cells for Cell Replacement Therapy in Neurodegenerative Diseases<br>*Chou Chai (Singapore)* |
| 15:20-15:50 | C1-I2 | Tissue Engineering And 3D Printing<br>*Shan-Hui Hsu 徐善慧 (Taiwan)* |
| 15:50-16:20 | C1-I3 | Therapeutic Potential of Amniotic Fluid Stem Cells in Neurogenesis<br>*Shiaw-Min Hwang 黃效民 (Taiwan)* |

# April 11 (Saturday) Ballroom II

## A2

### Frontier in iPS Cell & Epigenetics

| | | |
|---|---|---|
| 10:30-11:00 | A2-I1 | Feeder-Free Culture and Reprogramming of Human iPSCs on Dishes Grafted with Cell Adhesion Peptides and Having Different Elasticity<br>*Akon Higuchin (Japan)* |
| 11:00-11:30 | A2-I2 | Cell Reprogramming and iPSC Research in Retinal Diseases<br>*Shih-Hwa Chiou 邱士華 (Taiwan)* |
| 11:30-12:00 | A2-I3 | Human Ipsc-Derived Organ Bud Based Approaches Towards Clinical Application<br>*Takanori Takebe (Japan)* |

## B2

### Cutting Edges of Stem Cell & Immune Modulation

| | | |
|---|---|---|
| 13:00-13:30 | B2-I1 | Stem Cell-Based Therapies for Traumatic Brain Injury: Targeting the Secondary<br>*Cesario Borlongan (U.S.A)* |
| 13:30-14:00 | B2-I2 | Stem Cells, Neurokines and Biomaterials in Nerve Injury and Repair<br>*Ing-Ming Chiu 邱英明 (Taiwan)* |
| 14:40-14:30 | B2-I3 | Induction of Regulatory Macrophage-Like Cells from Mouse Pluripotent Stem Cells that Can Contribute to Suppress Allogeneic Immune Responses<br>*Ken-Ichiro Seino (Japan)* |

## C2

### Targeting Stem Cells: Trials and Translation

| | | |
|---|---|---|
| 14:50-15:20 | C2-I1 | Lumbosacral Spinal Cord Injury (Animals Studies)<br>*Wise Young (U.S.A)* |
| 15:20-15:50 | C2-I2 | Stem Cell Transplantation in Pediatric Malignancies: an Experience from India<br>*Sameer Bakhshi (India)* |
| 15:50-16:20 | C1-I3 | The Construction and Application of MSC-Based Tissue Engineered Nerve<br>*Xiaosong Gu (China)* |

## Panel Discussion

| | | |
|---|---|---|
| 16:30-17:00 | P1 | TBA |

# April 12 (Sunday) Ballroom I

## Keynote Speech [B]

| | | |
|---|---|---|
| 09:00-09:30 | K2-I1 | A Chemical Approach to Controlling Cell Fate<br>*Sheng Ding (U.S.A)* |
| 09:30-10:00 | K2-I2 | Immunological Applications of Stem Cells in Type 1 Diabetes<br>*Paolo Fiorina (U.S.A)* |
| 10:00-10:20 | K2-I3 | Scientist or Inventor? Entrepreneurship in Regenerative Medicine<br>*Paul R. Sanberg (U.S.A)* |

## D1

### Stem Cell Technology for Neurodegenerative Diseases

| | | |
|---|---|---|
| 10:40-11:10 | D1-I1 | Wnt-3A Signaling Mediated Neuroprotection and Regenerative Activities and Functional Recovery after Brain Injury<br>*Ling Wei (U.S.A)* |
| 11:10-11:40 | D1-I2 | Aberrant Astrocytes Cause Inflammation and Impair Vascular Reactivity in Huntington's Disease<br>*Yi-Juang Chern 陳儀莊 (Taiwan)* |
| 11:40-12:10 | D1-I3 | Promoting Adult Neurogenesis as a Strategy to Ameliorate Neurodegenerative Disease<br>*Young-Ji Shiao 蕭永基 (Taiwan)* |

## Luncheon Seminar

### StemCyte Taiwan Co., Ltd. 台灣永生細胞股份有限公司

| | | |
|---|---|---|
| 12:00-13:00 | L2 | TBA |

## E1

### Cutting Edges of Stem Cell & Immune Modulation

| | | |
|---|---|---|
| 13:10-13:40 | E1-I1 | Cancer Immunotherapy in Mice Using Antigen-Specific CTL from Stem Cells<br>*Jianxun Song (U.S.A)* |
| 13:40-14:10 | E1-I2 | Human Umbilical Cord Mesenchymal Stem Cells Treatment Improve the Liver Function in Decompensated Liver Cirrhosis Patients<br>*Fusheng Wang (China)* |
| 14:10-14:40 | E1-I3 | Clinical Applications of Intravenous Injection of Adipose Derived Stem Cells<br>*David CP Chen (U.S.A)* |

## F1

### Targeting Stem Cells: Trials and Translation

| | | |
|---|---|---|
| 15:00-15:30 | F1-I1 | Application of Hypoxic Mesenchymal Stem Cells for Therapies in Ischemic Limb: From Bench to Bedside<br>*Shih-Chieh Hung 洪士杰 (Taiwan)* |
| 15:30-16:00 | F1-I2 | Stem Cells Therapy for Stroke<br>*Toru Yamashita (Japan)* |
| 16:00-16:30 | F1-I3 | Neurorestoration Induced from Endogenous Stem Cells<br>*Sung Rae Cho (Korea)* |

# April 12 (Sunday) Ballroom I

## G1

### Stem Cell Technology for Neurodegenerative Diseases

| | | |
|---|---|---|
| 16:30-17:00 | G1-I1 | Optogenetic Stimulation of Striatal Glutamatergic Neurons Enhances Neurogenesis in the Subventricular Zone of Normal and Stroke Mice<br>*Shan Ping Yu (U.S.A)* |
| 17:00-17:30 | G1-I2 | Neuroprotection and Stem Cell Therapy in Japan<br>*Koji Abe (Japan)* |

# April 12 (Sunday) Ballroom II

## D2

### Cutting Edges of Stem Cell & Immune Modulation

| | | |
|---|---|---|
| 10:40-11:10 | D2-I1 | Muse Cells and Their Possible Application to Both Autologous and Allogenic Transplantation Therapy<br>*Mari Dezawa (Japan)* |
| 11:10-11:40 | D2-I2 | MAP4K Kinases and DUSP Phosphatases in Inflammation and T Cell-Mediated Diseases<br>*Tse-Hua Tan 譚澤華 (Taiwan)* |
| 11:40-12:10 | D2-I3 | Therapeutic Potential of Human Fetal-Stage Stem Cells<br>*B. Lin-Ju Yen 顏伶汝 (Taiwan)* |

## E2

### Frontier in iPS Cell& Epigenetics

| | | |
|---|---|---|
| 13:10-13:40 | E2-I1 | Systemic Combined Melatonin-Mitochondria Treatment Improves Rat Acute Respiratory Distress Syndrome<br>*Hong-Lin Su 蘇鴻麟 (Tawian)* |
| 13:40-14:10 | E2-I2 | Porcine Derived Induced Pluripotent Stem Cells with Six Reprogramming Factors<br>*Fukuda Tomokazu (Japan)* |
| 14:10-14:40 | E2-I3 | Generation of Pluripotent Stem Cells and Multipotent Neural Progenitors from Somatic Cell Reprogramming<br>*Chia-Ning Shen 沈家寧 (Taiwan)* |

## G2

### Emerging Drug Targets in Development and Discovery

| | | |
|---|---|---|
| 16:30-17:00 | G2-I1 | Design of Integrin Drugs for Cancer<br>*Woei-Jer Chuang 莊偉哲 (Taiwan)* |
| 17:00-17:30 | G2-I2 | Development Senescence-Based Targeting Drug for Glioblastoma Multiformis-2nd Generation Drug of Interstitial Chemotherapy<br>*Horng-Jyh Harn 韓鴻志(Taiwan)* |